» Articles » PMID: 15258199

Bezafibrate Stimulates Canalicular Localization of NBD-labeled PC in HepG2 Cells by PPARalpha-mediated Redistribution of ABCB4

Overview
Journal J Lipid Res
Publisher Elsevier
Specialty Biochemistry
Date 2004 Jul 20
PMID 15258199
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Fibrates, including bezafibrate (BF), upregulate the expression of ATP binding cassette protein B4 (ABCB4) through gene transcription in mice. To determine the effects of BF on the expression levels of ABCB4 and on the stimulation of biliary phosphatidylcholine (PC) transport in human HepG2 hepatoblastoma cells, mRNA and protein levels as well as subcellular localization were investigated in the cells treated with BF. The canalicular accumulation of a fluorescent PC was assessed by confocal laser scanning microscopy. Treatment with 300 micromol/l BF for 24 h increased levels of ABCB4 mRNA but not protein by up to 151%. BF caused redistribution of ABCB4 into pseudocanaliculi formed between cells. In association with this redistribution, BF accelerated the accumulation of fluorescent PC in bile canaliculi (up to 163% of that in nontreated cells). Suppression of peroxisome proliferator-activated receptor alpha (PPARalpha) expression by either a small interfering RNA duplex or morpholino antisense oligonucleotide attenuated the BF-induced redistribution of ABCB4. These findings suggest that BF may enhance the capacity of human hepatocytes to direct PC into bile canaliculi via PPARalpha-mediated redistribution of ABCB4 to the canalicular membrane. This provides a rationale for the use of BF to improve cholestasis and/or cholangitis that is attributable to hypofunction of ABCB4.

Citing Articles

Itching for Answers: A Comprehensive Review of Cholestatic Pruritus Treatments.

Gabrielli F, Crepaldi E, Cavicchioli A, Rivi M, Costanzo A, Cursaro C Biomolecules. 2024; 14(10).

PMID: 39456160 PMC: 11505983. DOI: 10.3390/biom14101227.


PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales.

Colapietro F, Gershwin M, Lleo A J Transl Autoimmun. 2023; 6:100188.

PMID: 36684809 PMC: 9850184. DOI: 10.1016/j.jtauto.2023.100188.


Novel therapeutic targets for cholestatic and fatty liver disease.

Trauner M, Fuchs C Gut. 2021; 71(1):194-209.

PMID: 34615727 PMC: 8666813. DOI: 10.1136/gutjnl-2021-324305.


Evaluating the effect of a mixture of two main conjugated linoleic acid isomers on hepatic steatosis in HepG2 cellular model.

Jalilian A, Golmohammadi T, Meshkani R, Koushki M, Eivazi N, Babaei Khorzoughi R Mol Biol Rep. 2021; 48(2):1359-1370.

PMID: 33580458 DOI: 10.1007/s11033-021-06203-5.


Alterations in cellular and organellar phospholipid compositions of HepG2 cells during cell growth.

Tsuji T, Morita S, Nakamura Y, Ikeda Y, Kambe T, Terada T Sci Rep. 2021; 11(1):2731.

PMID: 33526799 PMC: 7851136. DOI: 10.1038/s41598-021-81733-3.